BNTX
BioNTech SE
NASDAQ · Healthcare · Biotechnology · DE
$89.91
+3.44%Year over year
Reported trailing growth
- Revenue
- -23.4%
- EBITDA
- —
- EBIT
- -84.9%
- EPS
- —
- Free cash flow
- +18.9%
- Operating cash flow
- +26.4%
Forward estimates
Based on analyst estimates
- Revenue
- -32.3%
- EBITDA
- —
- EPS
- -47.7%
Three-year CAGR
- Revenue
- -45.8%
- EBITDA
- -71.1%
- EBIT
- +52.5%
- Net income
- -64.0%
- EPS
- -62.8%
- Free cash flow
- -72.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026